APOE and Cognitive impairment: APOE-ε4 carriers had a higher frequency of cognitive impairment (CDR score ≥ 0.5) (Fig. 2A), higher scores of Braak staging for NFT (Fig. 2B) and CERAD score for NP (Fig. 2C), and a higher frequency of CAA (Fig. 2D) than APOE-ε4 non-carriers.